Navigation Links
Valeant Pharmaceuticals Reports 2011 First Quarter Financial Results
Date:5/9/2011

tionalPro Forma Organic Growth - by SegmentFor the Three Months Ended March 31, 2011(In thousands) Three Months Ended March 31, Mar YTD
2011Pro forma
Mar YTD
2010 (c)%   ChangeMar YTD  2011 currency impactMar YTD excluding currency impact%
ChangeMar YTD
acquisition
impact at
2010 rates Mar YTD
excluding
currency &
acquisition
impactMar YTD
growth at
constant
currency,
net of
acquisitionsProduct Sales (a)(b)  U.S. Dermatology $   95,919$   73,41831%$
(25)$   95,89431%$
(6,531)$
89,36322%  U.S. Neurology & Other203,544189,7137%-203,5447%(20,625)182,919-4%Total U.S.299,463263,13114%(25)299,43814%(27,156)272,2823%Canada/Australia69,05058,77817%(4,415)64,63510%(3,843)60,7923%Specialty pharmaceuticals 368,513321,90914%(4,440)364,07313%(30,999)333,0743%Branded generics - Latin America 56,38342,05834%(3,260)53,12326%(6,471)46,65211%Branded generics - Europe 75,52549,55152%(98)75,42752%(17,042)58,38518%Branded Generics131,90891,60944%(3,358)128,55040%(23,513)105,03715%Total product sales500,421413,51821%(7,798)492,62319%(54,512)438,1116%Royalties20,74017,04122%-20,74022%-20,74022%Total organic revenue$ 521,161$ 430,55921%$  (7,798)$ 513,36319%$
(54,512)
$   458,8517%Organic Growth - excluding Diastat & EfudexDiastat adjustment$   (7,914)$ (15,864)-50%$
-$   (7,914)-50%$
-$
(7,914)-50%  
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Valeant to Acquire Polish Products
2. GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine
3. Valeant and Biovail Announce Results of Special Meetings of Shareholders
4. Valeant Pharmaceuticals Announces Redemption and Defeasance of 7.625% Senior Notes Due 2020 and 8.375% Senior Notes Due 2016
5. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
6. Valeant Pharmaceuticals Reports 2010 Third Quarter Financial Results
7. Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan
8. Valeant Announces Pricing of Senior Notes
9. Valeant Pharmaceuticals Announces Appointment of Robert A. Ingram and Resignation of William M. Wells as Chairman
10. Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO
11. Regulatory Update - GSK and Valeant Receive Positive Opinion in Europe From the CHMP for Trobalt (Retigabine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... LAKE, N.J. and SAN DIEGO ... Inc. (NASDAQ: ARNA ) announced today that an ... 3 trials of lorcaserin entitled, "Early Weight Loss While on ... Weight-Loss Outcomes," was recently published in the online issue of ... Obesity Society. The objective of these analyses was to identify ...
(Date:7/30/2014)... DALLAS , July 30, 2014 /PRNewswire-iReach/ -- ... on Global and Chinese Heparin sodium (CAS 9041-08-1) ... reviews the basic information of Heparin sodium (CAS ... application and manufacturing technology. The report then explores ... (CAS 9041-08-1) & calcium (CAS 37270-89-6) listing their ...
(Date:7/30/2014)...   Epic Sciences, Inc. ("Epic"), a ... novel diagnostics to personalize and advance the treatment ... of a $30 million Series C Preferred Stock ... and Arcus Ventures, existing investors Domain Associates, Roche ... as undisclosed individual investors. With the proceeds of ...
Breaking Medicine Technology:Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 2Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 3Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 4Heparin Sodium & Calcium Industry for Global and Chinese Markets Forecast to 2019 5Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 2Epic Sciences Announces Series C Financing to Advance Essential Cancer Diagnostics for Personalized Medicine 3
... NASHVILLE, Tenn., May 11, 2011 Cumberland Pharmaceuticals ... pharmaceutical company focused on hospital acute care and gastroenterology ... overview at the 2011 UBS Global Specialty Pharmaceuticals Conference ... p.m. The presentation will be simultaneously ...
... S.C., May 11, 2011 /PRNewswire-USNewswire/ -- ... announced that two client companies received big check investment ... Therapeutics and EnviroMix, both technology-based start-ups located in the ... technology and business model. Madeira Therapeutics was ...
Cached Medicine Technology:SC Launch Presents "Big Check" Investment to Two South Carolina Companies 2SC Launch Presents "Big Check" Investment to Two South Carolina Companies 3
(Date:7/31/2014)... 31, 2014 In its latest blog post, ... believes that having family close by during a stay in ... the process is successful, is looking at 10 tips to ... , “Addiction recovery is a lifelong process, and one that ... committed to without compromise,” commented Best Drug Rehabilitation’s CEO ...
(Date:7/31/2014)... The study, The Truth Behind ... episode of care payments for four clinical areas—congestive heart ... replacements (hips and knees). Using the definition of ... Care Improvement program, the study examines these clinical areas ... the country. , “Our study reaffirms that, in most ...
(Date:7/30/2014)... 30, 2014 The Mesothelioma ... Penn's Abramson Cancer Center, will host a regional ... experts in the field of mesothelioma. September 26 marks ... is open to the public, and specifically aimed at ... who have been exposed to asbestos. , The conference ...
(Date:7/30/2014)... returning National Guard soldiers were more likely to ... life setbacks, including job loss, legal problems, divorce, ... military families. Results of the study by researchers ... are published online in the American Journal ... a major concern for reservists returning home. Nearly ...
(Date:7/30/2014)... (PRWEB) July 31, 2014 “United States Orthopedic ... data on the United States Orthopedic Braces and Supports market. ... volume (in units) and average price data (in US dollars), ... Supports , Ankle Braces and Supports , ... Braces and Supports. , Orthotics is a specialty ...
Breaking Medicine News(10 mins):Health News:New Best Drug Rehabilitation Blog Posts Looks at 10 Tips for Coping After Drug or Alcohol Rehab 2Health News:Recent Research Finds a New Driver of Cost Variation in Episode Payments 2Health News:Recent Research Finds a New Driver of Cost Variation in Episode Payments 3Health News:September Events: Regional Conference on Mesothelioma in Philadelphia 2Health News:September Events: Regional Conference on Mesothelioma in Philadelphia 3Health News:Vets' alcohol problems linked to stress on the home front 2Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 2Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 3Health News:US Orthopedic Braces and Supports Market (Knee, Ankle & Spinal) to 2020 Report Available at MarketOptimizer.org 4
... released figures which show that there is an incredible ... for rehabilitation treatment programs under the banner of NHS(National ... . ,Most of the centers earmarked for drug ... the in- patient wards are empty and that referral ...
... floor spasm and pain, which may now be relieved by ... symptoms of this condition are heaviness, frequency or urgency in ... Abbott of the Royal Hospital For Women, Randwick conducted a ... effect of botox on women with pelvic spasms.30 women were ...
... Carnegie Mellon University conducted a path breaking study on ... in their ability to differentiate between living and non ... The paper which can be found in the Journal ... to one of the intriguing traits of autism: the ...
... The American College of Surgeons (ACS) has accredited NewYork-Presbyterian ... with the highest possible designation (1A),// in recognition of ... available. The top-level designation is a first for New ... ,An estimated 30 percent of U.S. adults 20 years ...
... a major recent countrywide study, antipsychotic drugs that are ... in treating Alzheimer's disease as most of the patients ... ,This study was conducted by Lon Schneider, professor ... the Keck School of Medicine of the University of ...
... develop pneumococcal pneumonia -- a common bacterial pneumonia that ... October issue of Mayo Clinic Women's HealthSource is spreading ... //against this form of pneumonia and reduces the serious ... unaware of the vaccine, or may not know that ...
Cached Medicine News:Health News:NHS De-addiction, Rehabilitation waiting time ticking into months 2Health News:Autistic Children May Lag behind in ‘Categorization of Objects 2Health News:NewYork-Presbyterian Receives Highest Accreditation for Bariatric Surgery 2
Desmarres Lid Retractor thin solid blades. Size 2....
... system introduces a new level ... microsurgical instrumentation. It has an ... with advanced microcomputer control of ... operate with a full range ...
Multiple Modulation Phaco (MMP) programmability with eight surgeon settings for maximum versatility. The combination of the peristaltic power balanced pump and the piezoelectric handpiece results in ...
... is a unique combination of Paradigm's ... flexibility for modular hardware modifications and ... of changing cataract surgical techniques and ... ophthalmic surgical platforms providing open architecture ...
Medicine Products: